Tetracycline-containing MCM-41 mesoporous silica nanoparticles for the treatment of Escherichia coli

Bhuvaneswari Koneru, Yi Shi, Yu Chieh Wang, Sai H. Chavala, Michael L. Miller, Brittany Holbert, Maricar Conson, Aiguo Ni, Anthony J. Di Pasqua

Research output: Contribution to journalArticlepeer-review

32 Scopus citations

Abstract

Tetracycline (TC) is a well-known broad spectrum antibiotic, which is effective against many Gram positive and Gram negative bacteria. Controlled release nanoparticle formulations of TC have been reported, and could be beneficial for application in the treatment of periodontitis and dental bone infections. Furthermore, TC-controlled transcriptional regulation systems (Tet-on and Tet-off) are useful for controlling transgene expression in vitro and in vivo for biomedical research purposes; controlled TC release systems could be useful here, as well. Mesoporous silica nanomaterials (MSNs) are widely studied for drug delivery applications; Mobile crystalline material 41 (MCM-41), a type of MSN, has a mesoporous structure with pores forming channels in a hexagonal fashion. We prepared 41 4 and 406 55 nm MCM-41 mesoporous silica nanoparticles with loaded TC for controlled drug release; TC content in the TC-MCM-41 nanoparticles was 18.7% and 17.7% w/w, respectively. Release of TC from TC-MCM-41 nanoparticles was then measured in phosphate-buffered saline (PBS), pH 7.2, at 37 C over a period of 5 h. Most antibiotic was released from both over this observation period; however, the majority of TC was released over the first hour. Efficacy of the TC-MCM-41 nanoparticles was then shown to be superior to free TC against Escherichia coli (E. coli) in culture over a 24 h period, while blank nanoparticles had no effect.

Original languageEnglish
Pages (from-to)19690-19698
Number of pages9
JournalMolecules
Volume20
Issue number11
DOIs
StatePublished - 30 Oct 2015

Keywords

  • Controlled drug release
  • E. coli
  • MCM-41
  • Tetracycline

Fingerprint

Dive into the research topics of 'Tetracycline-containing MCM-41 mesoporous silica nanoparticles for the treatment of Escherichia coli'. Together they form a unique fingerprint.

Cite this